News

According to Great Basin Scientific, the new round of financing will fund the company through the spring of 2009 as it completes the design of its rapid molecular

The company will occupy approximately 20,000sqft of office space located north of the San Francisco International Airport at 2000 Sierra Point Parkway, adjacent to Highway 101. The facility

The brain cancer test is a molecular diagnostic test developed and validated at The University of Texas MD Anderson Cancer Center to prospectively demonstrate responsiveness to treatment for

The company has previously announced a letter of intent to enter into a contractual arrangement with Qinba. Under the terms of this arrangement, Huifeng will assume operational control

According to the company, the versatile instrumentation and flexibility of the Apex system allows surgeons to match the surgical approach to the specific pathology of the patient. In

This payment is related to the transfer of Alnylam’s platform technology, including documents, materials, and know-how, to Takeda for the development of RNAi therapeutics. Alnylam has already received

The patent contains claims directed to inhibitory nucleic acid sequences targeting the ribonucleotide reductase subunit 2 (R2) gene, as well as pharmaceutical compositions and methods for inhibiting tumor

The trial, called Protex I, will enroll 50 patients at five sites in Europe. Follow-up examinations will be performed at 30 days, six months and nine months. The

Additionally, the company has also signed an agreement for distribution of the SmartSlide micro-incubation system with Takeda Rika Kogyo in Japan. These distributor agreements cover WaferGen’s entire family